The DRG model is now the dominant logic of hospital payment worldwide. Rather than reimbursing hospitals item by item for every drug, test, and bed-day, the payer assigns each admission to a group of clinically similar cases expected to consume similar resources, and pays a fixed sum per group. The design rewards efficiency: a hospital that treats a case for less than the group payment keeps the difference, while one that runs over absorbs the loss. But the mechanism only works fairly when the grouping is well calibrated. If a group lumps together cases with wildly different true costs, hospitals treating the expensive end of the distribution are systematically underpaid, and the payment standard itself becomes a hidden subsidy or penalty depending on which patients walk through the door.

The Chinese researchers set out to test precisely this property, which they call cost homogeneity, in the pediatric context. Their data came from the National Healthcare Security Administration and covered 289,026 pediatric inpatient encounters from January to June 2025. The team compared medical costs across adjacent diagnosis-related groups, the intermediate categories that sit beneath the final payment groups, and looked specifically at whether children with common diseases and children with idiopathic diseases, conditions whose origins are poorly understood and whose treatment pathways are often less predictable, generated comparable expenses within the same group.

The headline finding is a consistent gradient tied to hospital tier. Three adjacent diagnosis-related groups, labeled ES3, DT1, and EX2, all showed the same pattern: the higher the level of the hospital, the higher the average hospitalization expense for each subgroup. In other words, a child treated at a top-tier tertiary children’s hospital typically cost more to treat than a child with the same grouped diagnosis at a lower-level facility. That might sound unsurprising, since referral systems channel the sickest children upward, but it collides directly with the way China’s DRG payment standards are currently set. Under the prevailing arrangement, the payment for the same DRG group is uniform across hospitals of different tiers, with no adjustment for the variations in treatment costs that different levels of hospital actually incur.

The mismatch matters because the DRG framework in use was largely built around adult medicine. The authors argue that the existing grouping for pediatric cases needs to fully account for the unique characteristics of pediatric diseases rather than merely relying on a unified framework shared with adult patients. Children are not small adults, statistically or clinically. Their conditions evolve rapidly, diagnostic workups differ, length of stay patterns diverge, and rare or poorly understood disorders cluster in specialist children’s hospitals, which sit at the top of the hospital hierarchy and therefore at the expensive end of every tier-based gradient the study detected.

Two conditions crystallized the problem. The average hospitalization costs for Kawasaki disease, an inflammatory illness of young children that affects the blood vessels and is a leading cause of acquired heart disease in children worldwide, were significantly higher than those of the adjacent diagnosis-related group to which such cases were assigned, a difference the researchers report as statistically significant. The same held true for anorectal malformation complicated with rectal malformation, a congenital surgical condition requiring complex operative repair and often prolonged postoperative care. Both are exactly the kinds of cases that concentrate at national children’s centers, and both are exactly the kinds of cases a flat payment rate punishes.

The technical vocabulary of the paper deserves unpacking, because it explains why the findings are more than a bureaucratic complaint. The authors evaluated dispersion using measures such as the coefficient of variation, the ratio of the standard deviation to the mean, which expresses how spread out costs are relative to their average. A well-designed DRG group should show low within-group variation and clear between-group variation: patients in the same group should cost about the same, and patients in different groups should differ. When a group’s coefficient of variation is high, the fixed payment attached to it is essentially a lottery ticket, and the hospitals drawing the costly tickets lose money on cases they cannot refuse. The study’s evidence that idiopathic pediatric conditions and complex surgical anomalies inflate costs within their assigned groups is direct evidence that some pediatric groups fail this homogeneity test.

Why does this matter beyond the accounting department? Payment systems shape clinical behavior. If a hospital consistently loses money on Kawasaki disease admissions because the DRG rate was calibrated on a cost distribution that does not reflect tertiary pediatric practice, the institution faces pressure to limit such admissions, transfer complex children elsewhere, or skimp on the intensive workup these conditions demand. Conversely, if the rate is set too generously for the low-cost end of the distribution, lower-tier hospitals are rewarded in ways that may not correspond to quality. The study’s tier gradient suggests that a single national or regional price for a pediatric group cannot simultaneously be fair to a county hospital and to a national children’s center, because the case mix and cost structures at the two levels differ systematically.

The authors’ prescription follows directly from the diagnosis. They conclude that the implementation of DRG payment should take pediatric clinical characteristics into account, and they call for refined grouping adjustments to be performed for disease groups with high cost heterogeneity to improve the adaptability of the DRG system to pediatric cases. In practical terms, that could mean splitting groups whose internal variation is excessive, creating pediatric-specific categories rather than folding children into adult frameworks, and introducing tier-adjusted payment weights that acknowledge the real cost differences the study documented across hospital levels. The research was supported by the National Healthcare Security Administration, the very agency that administers the payment system, which signals institutional interest in getting the calibration right.

The stakes are considerable. China’s DRG-based payment reform is one of the largest health financing experiments in the world, covering hundreds of millions of insured patients, and pediatric care is a domain where the consequences of mispricing fall on some of the most vulnerable people in the system. A study of this scale, nearly three hundred thousand encounters across two major cities with different economic profiles, offers the kind of empirical grounding that payment reform rarely gets before the rules are locked in. Its message is deceptively simple: a payment system is only as good as its statistics, and for children, the statistics currently say the groups do not hold together. Until the grouping is refined, every Kawasaki disease admission and every complex congenital malformation repair quietly tests how much financial strain the system is willing to place on the hospitals that care for the sickest children.

Subject of Research: Cost homogeneity of pediatric inpatient care under China's DRG hospital payment system

Article Title: Evaluation of cost homogeneity among pediatric inpatients under DRG system: a study of inpatient encounters in Chengdu and Hangzhou, China

Article References: Song, F., Na, C., Lv, Y., Zang, Z., & Zhao, C. (2026). Evaluation of cost homogeneity among pediatric inpatients under DRG system: a study of inpatient encounters in Chengdu and Hangzhou, China. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07693-7

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07693-7

Keywords: DRG payment, pediatrics, hospital costs, cost homogeneity, Kawasaki disease, anorectal malformation, China, health policy, hospital tiers, case-mix grouping, healthcare financing, inpatient care

The research team, led by Ruhul Amin of the Bangladesh Institute of Governance and Management together with colleagues at Bangladesh University of Professionals, drew on cross-sectional data from a quasi-experimental project evaluating the fiscal stimulus packages disbursed by the Government of Bangladesh during the pandemic. Between July and August 2023, the team surveyed 751 microcredit entrepreneurs who were beneficiaries of eight different microfinance organizations. The respondents included marginal people and women entrepreneurs, groups that policymakers often target with concessional lending precisely because they are considered economically vulnerable yet capable of productive self-employment.

The analytical framework centered on the crowding-out effect, a well-established concept in health economics. In households without insurance or public coverage, medical bills are paid directly from the family budget, a pattern known as out-of-pocket or OOP expenditure. Because household budgets are finite, every taka spent at the pharmacy or the private clinic is a taka not spent elsewhere. Economists describe this trade-off as crowding out: health spending displaces consumption of other goods and services. For households living near subsistence, the displaced items are rarely luxuries. They are food, school fees, clothing, footwear, and transport, the very components of a minimum standard of living.

The study stratified households into three income groups and examined how OOP health expenses affected both non-food consumption and durable goods purchases. The results were striking in their asymmetry. Across the full sample, out-of-pocket health spending significantly crowded out household non-food consumption. But the impact was greatest among high-income households within this microcredit population, a finding that runs counter to the intuitive expectation that wealthier borrowers would be buffered against medical bills. The researchers also found that OOP health expenses significantly affected durable consumption expenses, such as purchases of household assets, specifically among high-income households.

One possible interpretation is that higher-income microcredit households have more discretionary spending to displace, so their consumption patterns register the shock more visibly in survey data. Poorer households may already be consuming at a floor below which they cannot fall, absorbing health costs instead by borrowing, selling assets, or forgoing care altogether. The study adds weight to this concern with a second key result: outstanding loans were found to be higher as a consequence of OOP health expenses in the middle- and high-income groups. In other words, medical spending did not merely reduce consumption; it pushed households deeper into debt, compounding the financial obligations they had already taken on through microcredit.

This debt dynamic is particularly corrosive in the microcredit context. Microfinance is designed to channel small loans into productive activities, with repayment schedules calibrated to expected business income. When a health emergency forces a household to divert loan capital or business revenue into medical bills, the arithmetic of repayment breaks down. The borrower may then take additional loans, often from informal moneylenders at higher interest rates, to cover both the medical costs and the microfinance installments. The study’s finding that outstanding loans rise with OOP health expenses suggests precisely this spiral, in which health shocks convert productive debt into a burden that undermines the developmental purpose of the original loan.

The timing of the research amplifies its significance. The COVID-19 pandemic placed extraordinary strain on household finances in Bangladesh and across South Asia. Lockdowns disrupted the small trading, tailoring, poultry raising, and food vending businesses that microcredit borrowers typically operate, while the illness itself generated direct medical costs and indirect income losses. Government stimulus packages, including concessional credit lines channeled through microfinance institutions, were intended to cushion these shocks. Yet the new evidence indicates that for many recipient households, healthcare spending remained a competing claim on scarce resources, blunting the stimulus effect that the credit support was designed to achieve.

Methodologically, the study benefits from a targeted sampling frame and institutional grounding. The dataset originated in a research project on the efficacy of pandemic-era fiscal stimulus, funded by the Strengthening Public Financial Management Program of Bangladesh’s Finance Division, and was analyzed with ethical approval from the Bangladesh Institute of Governance and Management’s Institutional Review Board. By surveying verified beneficiaries of eight microfinance organizations and segmenting them by income, the researchers could compare crowding-out effects across the economic spectrum within a single, well-defined population of borrowers. This design isolates the financial behavior of households that share similar access to credit but differ in income, making the income-group contrasts more meaningful than they would be in a general population sample.

The policy implications reach beyond Bangladesh’s borders. Out-of-pocket spending accounts for a large share of total health expenditure in many low- and middle-income countries, and health economists have long warned that such financing systems expose households to catastrophic health expenditures. The new study extends this warning to households that are often assumed to be protected by access to credit. The authors argue that the financial vulnerability created by high OOP health expenses requires integrated health and financial policies rather than isolated interventions in either sector. Their recommendations include strengthening public health services so that borrowers are not forced into costly private care, introducing health insurance schemes tailored to microcredit recipients, implementing targeted subsidy programs for medical emergencies, leveraging technology for service delivery, and promoting financial literacy so households can plan for health shocks.

For the global development community, the message is sobering. Microcredit has been celebrated and criticized in roughly equal measure over the past four decades, but this study identifies a specific, measurable channel through which its benefits can evaporate: the household medical bill. If a loan intended for a sewing machine is consumed by a hospital stay, the borrower is left with debt but no productive asset, and the poverty-reduction logic of microfinance collapses. The researchers’ evidence that this dynamic operated even among relatively high-income borrowers during the pandemic suggests that health financing reform is not merely a complement to financial inclusion but a precondition for it. Without protection against health shocks, the study concludes, the intended impact of microcredit support will continue to be undermined by the quiet arithmetic of the family budget, in which every taka spent on illness is a taka taken from dinner tables, schoolbooks, and the small businesses that development programs are built to nurture.

Subject of Research: The crowding-out effect of out-of-pocket healthcare expenditure on household consumption among microcredit recipient households in Bangladesh during the COVID-19 pandemic

Article Title: Association of out of pocket healthcare expenditure with household consumption among marginal people and women entrepreneurs in Bangladesh during the COVID 19 pandemic

Article References: Amin, R., Farabi, M. N. S., Gayen, K., & Dey, S. R. (2026). Association of out of pocket healthcare expenditure with household consumption among marginal people and women entrepreneurs in Bangladesh during the COVID 19 pandemic. Discover Social Science and Health. https://doi.org/10.1007/s44155-026-00464-w

Image Credits: AI Generated

DOI: 10.1007/s44155-026-00464-w

Keywords: out-of-pocket expenditure, crowding-out effect, microcredit, household consumption, healthcare financing, Bangladesh, COVID-19, women entrepreneurs, health insurance, financial vulnerability, health economics, microfinance

A new qualitative study published in the Journal of General Internal Medicine has now mapped out exactly why the gap between recommendation and reality persists in Hong Kong. Researchers from The Jockey Club School of Public Health and Primary Care at The Chinese University of Hong Kong conducted in-depth, one-on-one interviews with 35 stakeholders: 12 service recipients, 19 physicians drawn from public hospitals, private clinics and community organisations, and 4 policymakers involved in designing preventive health programmes. Rather than simply cataloguing opinions, the team structured their interviews and analysis around the updated Consolidated Framework for Implementation Research, or CFIR, one of the most widely used determinant frameworks in implementation science. CFIR organises the factors influencing whether an intervention succeeds into five domains: the innovation itself, the outer setting of policy and financing, the inner setting of the clinical organisation, the individuals involved, and the implementation process.

The interviews, each lasting roughly 30 minutes and conducted by Zoom or telephone, were transcribed verbatim in Chinese and analysed in two phases. First, the researchers performed an inductive thematic analysis to identify patterns emerging naturally from the data. Second, they re-examined those preliminary themes through the lens of the CFIR’s 2022 version, coding independently with NVivo software and resolving disagreements through discussion with senior investigators. The team followed the Standards for Reporting Qualitative Research, pilot-tested their interview guide, trained interviewers in CFIR constructs and cultural sensitivity, and recruited participants purposively until data saturation was reached within each stakeholder group. The result is one of the first multi-stakeholder portraits of osteoporosis screening feasibility in Hong Kong, and it reveals a striking pattern of convergence and divergence across the five CFIR domains.

Within the Innovation domain, which concerns perceptions of the intervention itself, the news was largely encouraging. Service recipients consistently framed screening as a proactive way to learn their fracture risk and act early, with one participant remarking that it would be best to check so that any problem could be treated earlier. Physicians agreed, emphasising that screening high-risk groups could prevent deterioration and benefit individuals, families and society, and they pointed to existing clinical guidelines from international organisations as evidence that screening rests on a solid, actionable framework. But policymakers introduced a sobering counterpoint: Hong Kong lacks local evidence on fracture incidence trends, cost-effectiveness and long-term outcomes. One policymaker asked pointedly whether any local studies existed to demonstrate disease trends, arguing that a committee should monitor such data before implementation decisions are made. The divide reflects fundamentally different evidentiary expectations: clinicians are satisfied with international guidance, while policymakers demand locally generated data to justify allocating scarce public resources.

Money emerged as the most consistent barrier across every stakeholder group. Service recipients described screening fees of several hundred to a few thousand Hong Kong dollars as prohibitive, particularly for elderly people on fixed incomes, and some said outright that they would not participate at current prices. Physicians echoed the concern, noting that even moderate fees deterred some patients and that large-scale rollout would be difficult because the general population would find the cost too high. Policymakers agreed that out-of-pocket costs directly affect participation. Beyond individual affordability, stakeholders raised the question of cost-effectiveness at the health-system level: physicians argued that academics needed to demonstrate how much money a territory-wide programme would actually save, given that fractures already cost the Hospital Authority substantial sums, while policymakers insisted that cost-effectiveness calculations and targeting of higher-risk groups, rather than universal screening, were prerequisites for any scale-up. In the Outer Setting domain, participants across all groups converged on subsidies and affordable access as the key facilitators, with suggestions ranging from partial government subsidies to partnerships with pharmaceutical companies, yet physicians and policymakers simultaneously worried that Hong Kong’s current economic climate makes new public spending unlikely.

The Inner Setting domain, which captures organisational capacity, exposed a second layer of difficulty. Service recipients and policymakers reported that information about osteoporosis and its screening is poorly disseminated, leaving potential participants confused and reluctant. One service recipient described seeing a flyer or two without understanding what screening involved, and therefore having little interest in exploring it further. Policymakers noted that frontline staff would need training before any rollout, since not everyone is familiar with the process. Physicians, for their part, emphasised resource constraints inside the clinic: severe manpower shortages, limited consultation time, inadequate facilities, and the absence of a supporting system to guide patients after a positive screen. Several physicians asked who would counsel patients on lifestyle modification or refer them to allied health professionals, noting that online resources alone are insufficient. Structured training and clear communication about eligibility and workflow were viewed as foundational, but the overall picture was of a healthcare system not yet equipped to translate a screening test into meaningful follow-up care.

At the level of Individuals, the study found a genuine wellspring of motivation among older residents. Many service recipients expressed a strong desire to know their bone health status, manage their diet and weight, and take responsibility for their own ageing bodies, and perceived susceptibility associated with ageing helped legitimise screening as timely and appropriate across all groups. Yet this personal motivation is undercut by low public awareness of osteoporosis itself. Policymakers in particular stressed that citizens have essentially no awareness of the disease, and that any policy would need to begin with sustained publicity and advertising campaigns. International literature supports this concern: studies in Denmark, Sweden and Australia show that people often regard bone fragility as an inevitable part of ageing, creating a false sense of security, while general practitioners frequently prioritise other conditions and view osteoporosis management as complex. Educational interventions grounded in behavioural theory, such as the theory of planned behavior, have been shown to improve knowledge, attitudes and preventive behaviors, suggesting that awareness campaigns could convert latent motivation into actual participation.

The Implementation Process domain revealed both the most creative proposals and the most structural pessimism. Service recipients wanted screening promoted through familiar community touchpoints, elderly centres, public hospitals, volunteers and social workers, arguing that trusted routine channels would normalise participation. Physicians envisioned a coordinated ecosystem in which non-governmental organisations, District Health Centres and private providers each play defined roles, citing an existing NGO-operated women’s health centre that already offers DXA scans with doctors on site as a model collaborative partner. They also called for multi-front public education combining awareness campaigns with practical guidance on diet, exercise and risk management. Policymakers, however, identified the hard barriers: limited coordination among stakeholders, no well-designated referral pathway, and the difficulty of reaching vulnerable populations. One policymaker invoked the inverse care law, the observation that health programmes tend to reach those who need them least, warning that the people most at risk and most in need of screening may be precisely the ones who never show up.

Taken together, the findings suggest that the barriers to osteoporosis screening in Hong Kong are not isolated problems but interacting ones. Reliance on out-of-pocket payment suppresses uptake, a pattern documented in previous Hong Kong screening studies where higher fees were associated with lower participation. Public-sector capacity pressures and long waiting times weaken confidence that a positive screen will lead to timely, actionable follow-up. Gaps in preventive-care awareness among older adults and disadvantaged communities mean that improving participation would itself demand counselling and navigation support, further straining limited frontline capacity. The authors argue that overcoming this cluster of challenges requires coordinated, multi-pronged action: government-subsidised or free screening for vulnerable populations, public-private partnerships to expand service capacity, clear care pathways with defined roles for primary care physicians, nurses and allied health professionals, community outreach including mobile screening units and senior centre education sessions, and culturally tailored campaigns to dispel misconceptions about bone fragility.

The study’s authors propose that the next step should be systematic rather than ad hoc: mapping the identified barriers and facilitators onto CFIR-Expert Recommendations for Implementing Change, or ERIC, a validated method for matching implementation strategies to contextual determinants, then refining candidate strategies through expert consensus methods such as Delphi panels and testing them in real-world settings. The researchers acknowledge limitations, including possible social desirability bias in interviews, purposive sampling that may introduce selection bias, and a small policymaker sample constrained by institutional recruitment limits. Still, as one of the first studies to bring patients, doctors and policymakers into a single implementation-focused conversation about osteoporosis in Hong Kong, the work offers a candid diagnosis of what stands between a well-evidenced screening test and a population that desperately needs it: money, manpower, coordination and, above all, awareness.

Subject of Research: Barriers and facilitators to implementing osteoporosis screening in Hong Kong from the perspectives of service recipients, physicians and policymakers

Article Title: Implementing Osteoporosis Screening in Hong Kong: A CFIR-Guided Qualitative Study of Multi-Stakeholder Perspectives

Article References: Zhong, C. C., Yim, M. K., Yang, Z., Chen, M., Lo, C. Y., Ng, S., Huang, J., & Wong, M. C. S. (2026). Implementing Osteoporosis Screening in Hong Kong: A CFIR-Guided Qualitative Study of Multi-Stakeholder Perspectives. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10680-4

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10680-4

Keywords: osteoporosis, DXA screening, Hong Kong, implementation science, CFIR, qualitative research, fragility fractures, primary care, health policy, bone mineral density, public awareness, healthcare financing